Newsletter April 2019

Open the PDF file below to read the full newsletter.

In this issue:

  • KL1333 in clinical trial – The starting pistol has been fired
  • Interview with MELAS patient Roger Kjell 
  • BioStock’s article NeuroVive wants to help patients with mitochondrial diseases

Read more about us and subscribe:

Follow us on LinkedIn

View our videos, interviews and presentations by subscribing to our YouTube channel


About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).




Documents & Links